| abstract |
The present disclosure provides cell populations enriched for CD57 negative T cells, or depleted for CD57 positive cells, and methods for stimulating, cultivating, expanding, and/or genetically engineering cell populations enriched for CD57- T cells or depleted for CD57+ T cells. Also included are methods for generating, isolating, enriching, or selecting CD57- T cells or depleting CD57+ cells, such as by negative selection. |